India performed record 18,900 organ transplants in 2024: Nadda
This is a significant leap from fewer than 5,000 transplants in 2013, he said, adding that India ranks third globally in the total number of organ transplants, behind only the United States of America and China.
The health minister added that India leads the world in hand transplants, showcasing our cutting-edge surgical capabilities and the unwavering dedication of our medical professionals.
Speaking at an event organised by the National Organ and Tissue Transplant Organisation (NOTTO) to mark the 15th Indian Organ Donation Day, Nadda said there is a significant gap between the number of patients who need transplants and the number of donors.
Addressing challenges
"There is an alarming rise in organ failure cases, posing a serious threat to public health and increasing strain on the healthcare system. Every year, thousands of people wait for organ transplants. Despite the urgent need, there remains a significant gap between the number of patients waiting for transplants and the number of available donors," he said.
"This gap is not due to lack of willingness but often due to lack of awareness and hesitation rooted in myths and misconceptions. That's why the organ donation day -- which gives us a platform to spread awareness, encourage conversation and honour the donors and their families -- is important," he stated.
Improved organ transplant rates
Highlighting the strides made by India in organ donation, Nadda stated that since the launch of Aadhaar-based NOTTO online pledge website in 2023, more than 3.30 lakh citizens have pledged their organs.
This surge in pledge registration reflects a growing awareness and dedication amongst the citizens towards this shared goal, Nadda said.
"Due to the unwavering dedication of our transplant professionals, India achieved a remarkable milestone of performing over 18,900 organ transplants in 2024, the highest ever recorded in a single year. This is a significant leap from fewer than 5,000 transplants in 2013. India ranks third globally in the total number of organ transplants, behind only the United States of America and China," he added.
Call for more discourse about organ donation
Pointing to the gap between requirement and availability, Nadda emphasised the need for greater awareness, more public dialogues, timely consent from families, and robust system to support donation.
"Each organ donor is a silent hero, someone whose selfless act transforms grief into hope and loss into lives. One person can save up to eight lives by donating heart, lungs, liver, kidneys, pancreas and intestines. Additionally, countless lives can be transformed through tissue donations," he said, adding that organ donation is one of the noblest acts.
Underlining government efforts, Nadda said, "Under the Rashtriya Arogya Nidhi, financial support of up to Rs 15 lakh is provided to poor patients for transplantation of kidneys, liver, heart and lungs. A support of up to Rs 10,000 per month is provided after the transplant to cover medical expenses. Kidney transplant package has also been included in the Ayushman Bharat Pradhan Mantri-Jan Arogya Yojana," he said.
Emphasising that unhealthy lifestyle and food habits are among the major factors leading to organ failure and hence it is necessary to take preventive measures and lifestyle interventions, he urged people to adopt yoga to promote overall well-being.
"Ayurveda and yoga offer simple practices to strengthen our organs and boost immunity. We must adopt yoga to promote overall well-being," Nadda said.
He added that Prime Minister has time and again encouraged everyone to take proactive steps towards better health. "One such powerful message is his call to reduce the consumption of oil by 10 per cent, a simple yet impactful step towards building a healthier disease-free future," Nadda said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
8 minutes ago
- Mint
Eris Lifesciences betting on insulin expertise to boost its GLP-1 play
Eris Lifesciences is gearing up to take advantage of India's booming diabetes-obesity market. The Ahmedabad-based drugmaker stands to gain in the country's human insulin market as innovator Novo Nordisk vacates, and it is betting on its insulin platform to grab a significant share in the anti-obesity market. 'We have a very successful insulin business with close to 10% market share in the country now. And any company that sells insulin well has been able to do GLP-1 very well," CEO Krishnakumar Vaidyanathan toldMintin an interview. Danish drugmaker Novo Nordisk, which is the innovator of blockbuster anti-obesity drugs Ozempic and Wegovy, is also a market leader in insulin, with an over 50% market share in India. The market for weight loss drugs in India was over ₹600 crore in July 2025. Also Read: Piramal Pharma's loss narrows to Rs82 crore in June quarter Vaidyanathan explained that the insulin business involves building a patient service and care platform, which goes beyond just selling the product. '...there is active support from Eris' side at the patient's residence…given this insulin platform, we are very confident that we'll be able to make a success of GLP-1 as well, because it will ride on this platform," he said. Eris says they have a 'one of a kind" patient service model where they train patients to use insulin, while Novo has a service model as well and a wide network of physicians. GLP-1s or glucagon-like peptide-1 agonists are a class of drugs used to treat type-2 diabetes and obesity, which mimic the GLP-1 hormone produced in the gut to regulate blood sugar and appetite. Eris plans to rely on third parties for Active Pharmaceutical Ingredients (APIs), but will eventually bring regular semaglutide in-house. It will depend on third parties for the synthetic semaglutide API. Eris launched liraglutide, a GLP-1, in India last year and plans to be among the first wave of launches for generic semaglutide, which goes off patent in March 2026. It is not the only one. India's top drugmakers, including Dr Reddy's,Cipla, Sun Pharma,Zydus Lifesciences, and Natco, are gearing up to launch the generic semaglutide next year. The firm also has a pipeline of standalone insulin analogues and insulin analogues with GLP-1 combinations in preclinical and clinical trials. Insulin dominance Earlier this year, Novo Nordisk announced the rollback of pen-filled versions of its best-selling Human Mixtard insulin. While the vial versions will still be sold, this opens up a huge market for domestic players to fill in the country's ₹4,500 crore insulin market. Eris acquired the Insugen and Basalog brands fromBiocon Biologics last year as part of a larger deal to acquire its branded formulations business. It also sells Xsulin through a joint venture with MJ Biopharma. Also Read: Jashvik Capital acquires stake in pharma software firm for ₹400 crore Apart from innovators Novo Nordisk andSanofi, which dominate the Indian insulin market, Lupin, which acquired Eli Lilly's Huminsulin brand last year, is a key domestic player. 'So this whole democratisation of insulins and GLP-1s is something that is going to happen. The ball has been set rolling," said Vaidyanathan. Eris expects to see increased sales from recombinant human insulin (RHI) pen products in November and December as innovator inventory runs out. The company is also planning to in-source its insulin and GLP-1 production at a later stage. The company commenced production of insulin vials at its Bhopal facility in Q1FY26, and expects to start cartridge production by Q4FY26. 'Our strategy has always been that, once we deem that a product is big and strategically important, then we bring it in-house," said Vaidyanathan. Eris Lifesciences reported its Q1FY26 results on Tuesday, with its consolidated revenue up 7.4% year-on-year to ₹773 crore. Its Ebitda for the quarter stood at ₹277 crore, up 11% YoY with a 36% Ebitda margin. Net profit was up 41% to ₹125 crore. The drugmaker is focused on increasing profitability and paring down debt in FY26. Also Read: Sun Pharma net profit falls on US antitrust settlement, drug impairment costs 'All of this will be accompanied by a significant acceleration in the EPS (earnings per share) and the return ratios," said Vaidyanathan. Its EPS in Q1 was ₹9.2, and the company expects a 50% EPS growth in FY26. The company's net debt in Q1FY26 was ₹2,317 crore, and it aims to reduce debt to ₹1,800 crore by the end of the year.
&w=3840&q=100)
Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
Time of India
3 hours ago
- Time of India
1 in 3 of Punjab's groundwater samples contains uranium beyond safe limits, Rajya Sabha told
Chandigarh: One-third of groundwater samples analysed by the Central Ground Water Board (CGWB) in Punjab have tested positive for toxic levels of Uranium, along with harmful concentrations of Arsenic, Fluoride, and Nitrate, raising serious public health concerns. Tired of too many ads? go ad free now Punjab has long struggled with groundwater contamination, often linked to industrial discharge, agricultural runoff, and poorly managed waste disposal systems. Such pollutants can cause severe health complications ranging from chronic illnesses to irreversible organ damage. In a written reply to MP Swati Maliwal in the Rajya Sabha on July 28, the Union ministry of state for jal shakti reported that 32.6% of groundwater samples tested in Punjab exceeded the permissible uranium limit of 0.03 mg/L—the highest contamination rate recorded among all tested parameters. In comparison, 10.7% of samples in Delhi crossed the same threshold. Elevated uranium levels in drinking water are known to cause kidney damage and other long-term health issues. Out of 908 samples analysed in Punjab, 296 contained uranium beyond the permissible limit. In addition, 13.8% of samples had fluoride levels above the safe limit of 1.5 mg/L, linked to ailments such as arthritis, infertility, hypertension, neurotoxicity, and a higher risk of skeletal cancer. Long-term exposure can also damage the liver, kidneys, and lungs. Out of 922 samples, 12.6% exceeded the nitrate limit of 45 mg/L, 4.8% were contaminated with arsenic beyond the 0.01 mg/L threshold, while 6.7% of samples showed electrical conductivity above 3000 µS/cm at 25°C, indicating high salinity levels in groundwater. These alarming findings come even as Punjab was declared 'Har Ghar Jal' in April 2023, with the state reporting functional household tap water connections (FHTCs) for all 34.27 lakh rural households across 11,977 villages. Tired of too many ads? go ad free now According to the ministry, under the Jal Jeevan Mission (JJM) guidelines, states and Union territories are required to take corrective action in cases of major water quality contamination. This includes alerting the health department for mitigation and initiating both short-term and long-term measures, particularly in cases involving uranium, arsenic, fluoride, or bacteriological contamination. Punjab govt has informed the Centre that remedial steps are initiated whenever contamination beyond permissible limits is detected—starting with immediate relief measures and followed by sustainable, long-term solutions. The Centre has also advised all states, including Punjab, to plan and implement piped water supply schemes based on alternative safe sources for villages facing water quality issues. Under JJM, 10% of total fund allocation is weighted towards populations residing in chemically contaminated habitations.
